Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine.

Drug Metab. Pharmacokinet. 22 (2): 103–112 (2007).

Regular Article

Morphine Glucuronosyltransferase Activity in Human Liver Microsomes is Inhibited by a Variety of Drugs that are Co-administered with Morphine

Yusuke HARA[1,2], Miki NAKAJIMA[1], Ken-ichi MIYAMOTO[2] and Tsuyoshi YOKOI[1,*]

[1]*Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan*
[2]*Kanazawa University Hospital, Kanazawa, Japan*

Full text of this paper is available at http://www.jstage.jst.go.jp/browse/dmpk

Summary: Morphine is an analgesic drug used for the treatment of acute and chronic pain syndromes for cancer patients. Glucuronidation is a major pathway of the elimination of morphine in humans. Morphine is metabolized to 3-glucuronide (no analgesic effect) and 6-glucuronide (more potently analgesic than morphine) mainly by UGT2B7. In the present study, we investigated the inhibitory effects of a variety of drugs on the morphine glucuronosyltransferase activities in human liver microsomes. Twenty-one drugs including anticancer drugs, immunosuppresants, analgesics, anticonvulsants, antidepressants, antipsychotic drugs were selected in this study, because they are frequently co-administered with morphine. We found that 10 out of 21 drugs, tamoxifen, tacrolimus, diclofenac, carbamazepine, imipramine, clomipramine, amitriptyline, diazepam, lorazepam and oxazepam extensively inhibited the morphine 3- and 6-glucuronosyltransferase activities. Although some of the drugs are not substrates of UGT2B7, they would be potent inhibitors of UGT2B7. If patients receive morphine and these drugs simultaneously, the drug-drug interaction may change the levels of morphine and these glucuronides, resulting in altered analgesic efficacy and the risk of side effects. The results presented here will assist clinicians in choosing the proper drugs and/or dosages, and enable them to anticipate potential drug-drug interactions.

Key words: UDP-glucuronosyltrasnferase; glucuronidation; drug-dug interaction; morphine

Introduction

Morphine is an analgesic drug used for the treatment of acute and chronic pain syndromes. It is used as the most practical and versatile analgesic for the relief of severe pain associated with advanced cancer in palliative care.[1)] Morphine is extensively glucuronidated, and this pathway accounts for approximately two-thirds of the elimination of morphine in humans. Morphine is metabolized to morphine 3- and 6-glucuronides by UDP-glucuronosyltransferases (UGTs) in liver.[2,3)] Morphine 3-glucuronidation is the dominant pathway. The metabolic clearance to morphine 3-glucuronide is about 5-fold higher than the metabolic clearance to morphine 6-glucuronide.[4)] Morphine 3-glucuronide has no analgesic effects, but morphine 6-glucuronide is a more potent (20 times) analgesic than morphine itself.[5)]

Patients suffering from cancer need continuous therapy with morphine. Anti-cancer drugs such as etoposide, irinotecan (its active metabolite is SN-38), and tamoxifen, are widely used for chemotherapy with morphine. Immunosuppressant drugs such as tacrolimus, cyclosporine A, and mycophenolate are sometimes used with morphine for the treatment of pain after organ transplantation. Cancer patients may also receive analgesics (diclofenac, acetaminophen, and naloxone), anticonvulsants (carbamazepine and valproic acid), and antidepressants (imipramine, clomipramine, amitriptyline, and desipramine) for the treatment of neuropathic pain from cancer. In addition, 10–30% of cancer patients have psychological distress.[6,7)] For the treatment of the psychological distress, benzodiazepine agonists (diazepam, lorazepam and oxazepam) and antipsychorotic drugs (olanzapine and milnacipran) are

Received; November 10, 2006, Accepted; February 1, 2007
**To whom correspondence should be addressed*: Tsuyoshi YOKOI, Ph.D., *Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. Tel. & Fax. +81-76-234-4407, E-mail: TYOKOI@kenroku.kanazawa-u.ac.jp*

used. Thus, morphine is frequently co-administered with a variety of drugs. Since the clearance of morphine is dependent on the metabolism by UGTs, drugs that inhibit UGTs might affect the kinetics of morphine and its glucuronides, resulting in altered analgesic efficacy and the risk of side effects. In the present study, we investigated the inhibitory effects of a variety of drugs that are frequently co-administered with morphine, on morphine glucuronidation in human livers in order to obtain useful information for predicting drug-drug interactions.

Materials and Methods

Chemicals and reagents: Morphine hydrochloride was purchased from Takeda Chemical Industries (Osaka, Japan). Morphine 3- and 6-glucuronides were generous gifts from Dr. Kazuta Oguri, Kyushu University (Fukuoka, Japan). Etoposide, tamoxifen citrate, cyclosporine A, mycophenolate, acetaminophen, valproic acid, carbamazepine, imipramine hydrochloride, clomipramine hydrochloride, amitriptyline hydrochloride, desipramine hydrochloride, diazepam, lorazepam, oxazepam were purchased from Wako Pure Chemical Industries (Osaka, Japan). Diclofenac, naloxone, uridine 5′-diphosphoglucronic acid (UDPGA), and alamethicin were purchased from Sigma-Aldrich (St. Louis, MO). Tacrolimus was purchased from Calbiochem (La Jolla, CA). Olanzapine was from Toronto Research Chemicals (Toronto, Canada). Irinotecan and SN-38 were kindly provided by Yakult (Tokyo, Japan). Milnacipran hydrochloride was kindly provided by Asahikasei Pharma (Tokyo, Japan). Pooled human liver microsomes were obtained from BD Gentest (Woburn, MA). All other chemicals were of the highest grade commercially available.

Morphine glucuronosyltransferase activity: Morphine glucuronosyltransferase activity was determined as described previously[8] with slight modifications. A typical incubation mixture (0.2 mL total volume) contained 50 mM Tris-HCl buffer (pH 7.4), 5 mM $MgCl_2$, 5 mM UDPGA, 25 μg/mL alamethicin, 0.25 mg/mL microsomal protein and 25–200 μM morphine. Each drug, which was dissolved in methanol, was added as an inhibitor so that the final concentration of solvent in the incubation mixture was $<1\%$. The reaction was initiated by the addition of UDPGA. After incubation at 37°C for 30 min, the reaction was terminated by the addition of 0.1 mL of ice-cold perchloric acid. After the removal of protein by centrifugation at 10,000 *g* for 5 min, a 100 μL portion of the supernatant was subjected to HPLC. Chromatography was performed using an L-2130 pump (Hitachi, Tokyo, Japan), an L-2480 FL detector (Hitachi), an L-2200 autosampler (Hitachi), a D-2500 integrator (Hitachi), and an L-2300 column oven (Hitachi). The flow rate was 0.8 mL/min and the column temperature was 35°C. The glucuronides were detected fluorometrically (excitation: 210 nm; emission: 350 nm) with a noise-base clean Uni-3 (Union, Gunma, Japan). The analytical column was a Develosil C30 (4.6 $\times$ 150 mm; 5 μm) column (Nomura Chemical, Aichi, Japan) and the mobile phase was 50 mM sodium dihydrogen phosphate (pH 4.5). The retention times of morphine 3-glucuronide, morphine 6-glucuronide, and morphine were 18.5, 31.0 and 37.5 min, respectively. The quantification of the metabolites was performed by comparing the HPLC peak heights to those of authentic standards. Limits of detection of morphine 3- and 6-glucuronides were 20 fmol and 200 fmol, respectively. It was also confirmed that intra-day and inter-day precision and accuracy of the detection of the glucuronides were $<10\%$ (data not shown). The formation of morphine 3- and 6-glucuronides by human liver microsomes increased linearly with an incubation time up to 60 min and with a protein concentration up to 0.75 mg/mL. Unless specified, an incubation time of 30 min and 0.25 mg/mL microsomal protein were used. All data were analyzed using the mean of duplicate determinations. The variances between the duplicate determinations were $<10\%$.

Data analyses: Lineweaver-Burk plots were used for the determination of the type of inhibition,[9] and Dixon plots were used as a secondary method. Kinetic parameters were determined by a nonlinear regression analysis using a computer program (K-cat, BioMetallics, Princeton, NJ).

Prediction of *in vivo* drug-drug interactions from *in vitro* data: If an enzyme reaction is inhibited competitively or noncompetitively by other drugs, when the substrate concentration is much lower than K_m, the change in the intrinsic clearance (CL_{int}) is expressed by the following equation[10]:

$$CL_{int}(+\text{inhibitor})/CL_{int}(-\text{inhibitor}) = 1/(1+I/K_i)$$

where I is the concentration of the inhibitor and K_i is the inhibition constant. When we discuss drug-drug interactions *via* the inhibition of enzymes, it is important that the concentration of the inhibitor refers to the concentration of the drug around the enzyme. It is difficult to know the actual concentrations of drugs at the active site of UGT. The changes of CL_{int} caused by co-administered drugs can be predicted using the maximum unbound concentrations in the liver. Since data of the concentrations in the liver and protein binding of each drug in tissues are largely not available, the maximum plasma concentrations were alternatively used in the present study.

Anticancer drug



Etoposide



Irinotecan



SN-38



Tamoxifen

Immunosuppresant



Tacrolimus



Cyclosporine A



Mycophenolate

Analgetic drug



Dicrofenac



Acetaminophen

Opioid antagonist



Naloxone

Fig. 1. Structure of drugs used in the present study.

Anticonvulsant



Valproic acid



Carbamazepine

Tricyclic antidepressant



Imipramine



Clomipramine



Amitriptyline



Desipramine

Benzodiazepine agonist



Diazepam



Lorazepam



Oxazepam

Antipsychotic drug



Olanzapine



Milnacipran

Fig. 1. Continued

Results

Inhibitory effects of drugs on morphine glucuronosyltransferase activities in human liver microsomes: Twenty-one drugs (500 μM) were screened for the inhibitory effects on morphine 3- and 6-glucuronosyltransferase activities at a 50 μM substrate concentration. As shown in **Fig. 2**, the morphine 3- and 6-glucuronosyltransferase activities were strongly inhibited by tamoxifen, diclofenac, imipramine, clomipramine, amitriptyline, desipramine, diazepam, lorazepam and oxazepam (<20% of control). The activities were also moderately inhibited by tacrolimus, mycophenolate, naloxone, carbamazepine, and olanzapine (20–50% of control), and weakly inhibited by irinotecan and valproic acid (50–70% of control). Interestingly, the morphine glucuronosyltransferase activities were activated by cyclosporine A (120%). For 14 drugs showing >50% inhibition at 500 μM, the IC_{50} values were determined by dose response curves with various



Fig. 2. Inhibitory effects of drugs on morphine glucuronosyltransferase activities in human liver microsomes. The concentrations of morphine and each drug were 50 μM and 500 μM, respectively. Each column represents the mean of duplicate determinations. The control activities in the pooled human liver microsomes were 23.1 pmol/min/mg protein for morphine 3-glucuronosyltransferase activity and 5.4 pmol/min/mg protein for morphine 6-glucuronosyltransferase activity. ND, not detected.

concentrations. The IC_{50} values are summarized in **Fig. 2**. The IC_{50} values of each drug were similar between the morphine 3- and 6-glucuronosyltransferase activities.

Inhibition constant and inhibition pattern: We determined the inhibition constant (K_i) values for 14 drugs that inhibited the morphine glucuronosyltransferase activities (IC_{50} values were $<500\,\mu$M), **(Fig. 3 and Table 1)**. The K_{is} and K_{ii} values are inhibition constants on the slope (competitive) and on the intercept (noncompetitive), respectively. Tamoxifen, mycophenolate, diclofenac, diazepam, and olanzapine exhibited noncompetitive inhibition for both the morphine 3- and 6-glucuronosyltransferase activities. Tacrolimus, carbamazepine, and lorazepam exhibited a mixed type of competitive and noncompetitive inhibition for both activities. Naloxone, imipramine, clomipramine, amitriptyline, and desipramine exhibited noncompetitive and mixed type inhibitions for morphine 3- and 6-glucuronosyltransferase activities, respectively. Oxazepam exhibited competitive and mixed type inhibitions for morphine 3- and 6-glucuronosyltransferase activities, respectively. All compounds except naloxone and olanzapine more potently inhibited the morphine 6-glucuronosyltransferase activity than the morphine 3-glucuronosyltransferase activity.

Predicted change of *in vivo* clearance of morphine by a variety of drugs from *vitro* data: To predict the possibility of drug-drug interaction *via* a metabolic process between morphine and the 14 drugs, the $1+I/K_i$ values were calculated **(Table 1)**. Carbamazepine showed the highest $1+I/K_i$ values (1.4 and 1.9 for morphine 3- and 6-glucuronosyltransferase activities, respectively). The values by diclofenac were both 1.4 for morphine 3- and 6-glucuronosyltransferase activities. Mycophenolate, clomipramine, diazepam and



Fig. 3. Typical Lineweaver-Burk plots of morphine glucuronosyltransferase activities in human liver microsomes. Effects of oxazepam (A, B) or naloxone (C, D) on morphine 3-(A, C) and 6-(B, D) glucuronosyltransferase activities were investigated. Each data point represents the mean of duplicate determinations. Lines were drawn by linear regression analysis.

Table 1. Inhibition of morphine 3- and 6-glucuronosyltransferase activity in human liver microsomes by 14 drugs.

Drug	I (μM)	Morphine 3-glucuronosyltransferase activity				Morphine 6-glucuronosyltransferase activity			
		K_{is} (μM)	K_{ii} (μM)	Inhibitory type	$1+I/K_i$	K_{is} (μM)	K_{ii} (μM)	Inhibitory type	$1+I/K_i$
Tamoxifen	0.48		81	Noncompetitive	1.0		27	Noncompetitive	1.0
Tacrolimus	0.04	347	95	Mixed	1.0	101	46	Mixed	1.0
Mycophenolate	60		713	Noncompetitive	1.1		296	Noncompetitive	1.2
Diclofenac	9.4		22	Noncompetitive	1.4		24	Noncompetitive	1.4
Naloxone	0.05		518	Noncompetitive	1.0	1298		Competitive	1.0
Carbamazepine	42	243	118	Mixed	1.4	78	47	Mixed	1.9
Imipramine	1.9		81	Noncompetitive	1.0	60	33	Mixed	1.1
Clomipramine	1.4		20	Noncompetitive	1.1	19	6	Mixed	1.2
Amitriptyline	0.8		248	Noncompetitive	1.0	111	30	Mixed	1.0
Desipramine	1.1		177	Noncompetitive	1.0	458	111	Mixed	1.0
Diazepam	1.8		47	Noncompetitive	1.0		9	Noncompetitive	1.2
Lorazepam	0.2	239	53	Mixed	1.0	65	17	Mixed	1.0
Oxazepam	5	519		Competitive	1.0	41	93	Mixed	1.2
Olanzapine	0.04		196	Noncompetitive	1.0		266	Noncompetitive	1.0

The K_{is} and K_{ii} values are inhibition constants on the slope (competitive) and on the intercept (noncompetitive), respectively.
In the case of mix-type inhibition, the lower K_i was used in the calculation.
The plasma concentration of oxazepam was from Court *et al.*,[19] and those of the other drugs were from Gilman *et al.*[24]

oxazepam showed the $1+I/K_i$ values of 1.2 for the morphine 6-glucuronosyltransferase activity. Since most compounds more potently inhibit morphine 6-glucuronosyltransferase activity than morphine 3-glucuronosyltransferase activity, the ratio of 3-glucuronide/6-glucuronide in plasma would be increased, changing the analgesic efficacy and the risk of side effects.

Discussion

Morphine is mainly metabolized to 3- and 6-glucuronides by UGT enzymes. Morphine 3-glucuronidation is catalyzed by multiple isoforms such as UGT2B7, UGT1A8, and UGT1A3 with relatively low K_m values (0.4–3.2 mM) as well as UGT1A10, UGT1A6, UGT1A1, and UGT1A9 with relatively high K_m values (13–37 mM).[3] In contrast, morphine 6-glucuronidation is specifically catalyzed by UGT2B7 ($K_m = 1.0$ mM).[3] Collectively. UGT2B7 is recognized as a major isoform catalyzing the glucuronidation of morphine. In the presents study, we investigated the inhibitory effects of 21 drugs on the morphine glucuronosyltransferase activities. Although the K_m values of the morphine glucuronosyltransferase activities are high as mM order, the inhibitory effects were investigated with the substrate concentrations at μM order by considering the plasma concentrations in clinical practice[11] and the detection limits of morphine glucuronides in the HPLC system.

Among 21 drugs used in the present study, diclofenac, clomipramine, and amitriptyline have been reported to affect the pharmacokinetics of morphine *in vivo*. Tighe *et al.*[11] have reported that the plasma concentration of morphine 6-glucuronide was decreased by 40% with co-administration of diclofenac. Diclofenac is known to be mainly metabolized by P450s, but also metabolized by UGTs (**Table 2**). The affinity of diclofenac to UGT2B7 ($K_m = 25$ μM) is higher than that of morphine.[12] In the present study, we found that diclofenac potently inhibited the morphine glucuronosyltransferase activities in a noncompetitive manner. The extent of *in vivo* inhibition can be predicted quantitatively by the calculation of $1/(1+I/K_i)$ from an *in vitro* study. The $1+I/K_i$ values by diclofenac were 1.4, indicating that the change of the plasma concentration would be due to the inhibition of morphine glucuronidation by diclofenac. Ventafridda *et al.*[13] reported that co-administration of clomipramine and amitriptyline increased the area under the curve (AUC) of morphine approximately 2 fold in humans. Tricyclic antidepressants including clomipramine and amitriptyline are known to be substrates of UGT1A3 and UGT1A4 (**Table 2**). However, we found that clomipramine (K_i values were 6–20 μM) and amitriptyline (K_i values were 30–248 μM) strongly inhibited the morphine glucuronidations. These results are in accordance with a previous study by Wahlstrom *et al.*[14] reporting that clomipramine (K_i values were 56–90 μM) and amitriptyline (K_i values were 80–160 μM) inhibited morphine glucuronidations in human liver microsomes. The $1+I/K_i$ values by clomipramine were at most 1.2, but those by amitriptyline were 1.0, indicating that the prediction of *in vivo* inhibition from *in vitro* data might be unsuccessful. For drugs that are cleared predominantly through CYP-mediated metabolism, there is growing evidence that successful prediction of *in vivo* drug interactions through the inhibition of metabolism can be made from *in vitro* data. In contrast, drugs that are mainly metabolized by UGT appear to be

Table 2. Drugs used in this study and the involvement of UGTs in their metabolism.

Drug	UGT isoforms	K_m (μM)	Excretion as glucuronide
Etoposide	UGT1A1[25]	503	15–30%[26]
Irinotecan	UGT1A1[27]	unknown	unknown
SN-38	UGT1A1[28]	24	14.7%[29]
	UGT1A4	147	
	UGT1A6	97	
	UGT1A9	13	
	UGT2B15	186	
Tamoxifen	UGT1A4[21]	32	unknown
Tacrolimus	UGT2B7[30]	449	unknown
Cyclosporine	UGT2B7[31]	202	unknown
Mycophenolate	UGT1A1[8]	185	96%[32]
	UGT1A7	30	
	UGT1A8	298	
	UGT1A9	291	
	UGT1A10	119	
Diclofenac	UGT1A3[12]	12	5–10%[33]
	UGT2B7	25	
Acetaminophen	UGT1A1[34]	9400	63%[35]
	UGT1A6	2200	
	UGT1A9	20900	
Naloxone	UGT1A3[36]	unknown	unknown
	UGT2B7	unknown	
Carbamazepine	UGT2B7[15]	214	15%[37]
Valproic acid	UGT1A6[38]	3200	10%[39]
	UGT1A9	5200	
	UGT2B7	2100	
Imipramine	UGT1A3[40]	472	0.1–0.8%[41]
	UGT1A4	310	
Clomipramine	UGT1A3[40]	unknown	0.1–0.8%[41]
	UGT1A4	unknown	
Amitriptyline	UGT1A3[40]	267	26%[42]
	UGT1A4	170	
Desipramine	UGT1A3[40]	unknown	0.1–0.8%[41]
	UGT1A4	unknown	
Diazepam	unknown	unknown	unknown
Lorazepam	UGT2B7[18]	unknown	86%[43]
	UGT2B15[19]	unknown	
Oxazepam	UGT2B7[18]	203	67%[45]
	UGT2B15[44]	32	
Olanzapine	UGT1A4[46]	227	25%[47]
Milnacipran	unknown	unknown	30%[48]

less well-predicted using *in vitro* data. This may be due to the nature of UGT, latency restricting the access of substrates or UDPGA and the removal of formed glucuronide. Thus, for drugs that are mainly metabolized by UGT, the calculation of $1+I/K_i$ may not necessarily give a plausible prediction. We found that imipramine and desipramine also prominently inhibited the morphine glucuronosyltransferase activities. Although the $1+I/K_i$ was at most 1.1, it might be necessary to pay attention to the co-administration of these tricyclic antidepressants with morphine.

By calculation of the $1+I/K_i$ value, it was predicted that carbamazepine might cause drug-drug interactions with morphine. Carbamazepine is mainly metabolized by P450s, but also glucuronidated by UGT2B7 (**Table 2**).[15] The affinity of carbamazepine to UGT2B7 ($K_m=214\,\mu M$) is higher than that of morphine.[15] Although the contribution of UGT to carbamazepine metabolism might be low, our data suggest that the co-administration of carbamazepine and morphine should be avoided in clinical practice.

We found that benzodiazepine agonists have inhibitory effects on the morphine glucuronosyltransferase activities. The order of inhibitory potencies was diazepam > lorazepam > oxazepam. The results were consistent with a previous report that these drugs inhibit zidovudine glucuronosyltransferase activity catalyzed by UGT2B7 in human liver microsomes.[16,17] Lorazepam and oxazepam are mainly metabolized by UGT2B7 and 2B15,[18,19] whereas diazepam is mainly metabolized to oxazepam by CYPs.[20] It is clearly demonstrated that these drugs are potent inhibitors of UGT2B7. Co-administration of these benzodiazepine agonists with morphine should also be avoided.

Tamoxifen and tacrolimus strongly inhibited the morphine glucuronosyltransferase activities. Although tamoxifen has been reported to be a substrate of UGT1A4,[21] it is a potent inhibitor of UGT2B7 (K_i values were 27–81 μM), like tricyclic antidepressants. Tacrolimus, which is a substrate of UGT2B7, inhibited morphine glucuronosyltransferase activities with a mixed type of competitive and noncompetitive inhibition (K_i values were 46–347 μM). A drug-drug interaction between morphine and tamoxifen or tacrolimus might be possible.

Recently, it was reported that ketoconazole, which is a well-known inhibitor of CYP3A4, potently inhibits the morphine glucuronosyltransferase activity catalyzed by recombinant UGT2B7 (K_i values were 110–120 μM).[22] The possibility has been suggested that CYPs may interact with UGTs to modulate the function of UGTs.[23] The drugs showing potent inhibitory effects on morphine glucuronidation (**Table 1**) were substrates of CYPs (clomipramine, amitriptyline, tamoxifen: CYP2D6, diclofenac: CYP2C9, diazepam, lorazepam: CYP3A4). It would be interesting to investigate whether possible interaction between these CYP isoforms and UGT2B7 might be related to the inhibitory effects.

In conclusion, we found that tamoxifen, tacrolimus, diclofenac, carbamazepine, imipramine, clomipramine, amitriptyline, diazepam, lorazepam and oxazepam have prominent inhibitory effects on morphine glucuronidation. If patients receive morphine and these drugs simultaneously, drug-drug interactions may result in changed analgesic efficacy and risk of side effects. Such understanding is important so that clinicians can choose the proper drugs and/or dosages, and anticipate potential drug-drug interactions.

Acknowledgement: We acknowledge Brent Bell for reviewing the manuscript.

This work was supported in part by the Grant-in-Aid for Cancer Research (17-8) from the Ministry of Health, Labor and Welfare of Japan.

References

1) Donnelly, S., Davis, M. P., Walsh, D. and Naughton, M.: Morphine in cancer pain management: a practical guide. *Support Care Cancer*, **10**: 13–35 (2002).
2) Coffman, B. L., Rios, G. R., King, C. D. and Tephly, T. R.: Human UGT2B7 catalyzes morphine glucuronidation. *Drug Metab. Dispos.*, **25**: 1–4 (1997).
3) Stone, A. N., Mackenzie, P. I., Galetin, A., Houston, J. B. and Miners, J. O.: Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. *Drug Metab. Dispos.*, **31**: 1086–1089 (2003).
4) Milne, R. W., Nation, R. L. and Somogyi, A. A.: The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. *Drug Metab. Rev.*, **28**: 345–472 (1996).
5) Lotsch, J., Skarke, C., Tegeder, I. and Geisslinger, G.: Drug interactions with patient-controlled analgesia. *Clin. Pharmacokinet.*, **41**: 31–57 (2002).
6) Akechi, T., Okamura, H., Nishiwaki, Y. and Uchitomi, Y.: Psychiatric disorders and associated and predictive factors in patients with unresectable non small cell lung carcinoma: a longitudinal study. *Cancer*, **92**: 2609–2622 (2001).
7) Uchitomi, Y., Mikami, I., Nagai, K., Nishiwaki, Y., Akechi, T. and Okamura, H.: Depression and psychological distress in patients during the year after curative resection of non-small-cell lung cancer. *J. Clin. Oncol.*, **21**: 69–77 (2003).
8) Milne, R. W., Nation, R. L., Reynolds, G. D., Somogyi, A. A. and Van Crugten, J. T.: High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. *J. Chromatogr.*, **565**: 457–464 (1991).
9) Segel, I. H.: Rapid equilibrium partial and mixed type

inhibition. *In. Enzyme. Kinetics*, A Wiley-Interscience Publication, New York, 2004, pp. 161–226.
10) Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H. and Sugiyama, Y.: Prediction of pharmacokinetic alteration caused by drug-drug Interactions: Metabolic interaction in the liver. *Pharmacol. Rev.*, **50**: 387–411 (1998).
11) Tighe, K. E., Webb, A. M. and Hobbs, G. J.: Persistently high plasma morphine-6-glucuronide levels despite decreased hourly patient-controlled analgesia morphine use after single-dose diclofenac: potential for opioid-related toxicity. *Anesth. Analg.*, **88**: 1137–1142 (1999).
12) Sakaguchi, K., Green, M., Stock, N., Reger, T. S., Zunic, J. and King, C.: Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. *Arch. Biochem. Biophys.*, **424**: 219–225 (2004).
13) Ventafridda, V., Bianchi, M., Ripamonti, C., Sacerdote, P., De Conno, F., Zecca, E. and Panerai, A. E.: Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man. *Pain*, **43**: 155–162 (1990).
14) Wahlstrom, A., Lenhammar, L., Ask, B. and Rane, A.: Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation. *Pharmacol. Toxicol.*, **75**: 23–27 (1994).
15) Staines, A. G., Coughtrie, M. W. and Burchell, B.: N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. *J. Pharmacol. Exp. Ther.*, **311**: 1131–1137 (2004).
16) Grancharov, K., Naydenova, Z., Lozeva, S. and Golovinsky, E.: Natural and synthetic inhibitors of UDP-glucuronosyltransferase. *Pharmacol. Ther.*, **89**: 171–186 (2001).
17) Barbier, O., Turgeon, D., Girard, C., Green, M. D., Tephly, T. R., Hum, D. W. and Belanger, A.: 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). *Drug Metab. Dispos.*, **28**: 497–502 (2000).
18) Liston, H. L., Markowitz, J. S. and DeVane, C. L.: Drug glucuronidation in clinical psychopharmacology. *J. Clin. Psychopharmacol.*, **21**: 500–515 (2001).
19) Court, M. H., Duan, S. X., Guillemette, C., Journault, K., Krishnaswamy, S., von Moltke, L. L. and Greenblatt, D. J.: Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): *S*-oxazepam is glucuronidated by UGT2B15, while *R*-oxazepam is glucuronidated by UGT2B7 and UGT1A9. *Drug Metab. Dispos.*, **30**: 1257–1265 (2002).
20) Mandelli, M., Tognoni, G. and Garattini, S.: Clinical pharmacokinetics of diazepam. *Clin. Pharmacokinet.*, **3**: 72–91 (1978).
21) Kaku, T., Ogura, K., Nishiyama, T., Ohnuma, T., Muro, K. and Hiratsuka, A.: Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. *Biochem. Pharmacol.*, **67**: 2093–2102 (2004).
22) Takeda, S., Kitajima, Y., Ishii, Y., Nishimura, Y., Mackenzie, P. I., Oguri, K. and Yamada, H.: Inhibition of UDP-glucuronosyltransferase 2B7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. *Drug Metab. Dispos.*, **34**: 1277–1282 (2006).
23) Fremont, J. J., Wang, R. W. and King, C. D.: Coimmunoprecipitation of UDP-glucuronosyltransferase isoforms and cytochrome P450 3A4. *Mol. Pharmacol.*, **67**: 260–262 (2005).
24) Gilman, A. G., Joel, G., Hardman, J. G. and Limbird, L. E.: The Pharmaceutical Basis of Therapeutics 10th edition, Macmillan PC, New York, 2001, pp. 1948.
25) Watanabe, Y., Nakajima, M., Ohashi, N., Kume, T. and Yokoi, T.: Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. *Drug Metab. Dispos.*, **31**: 589–595 (2003).
26) Hande, K. R., Wedlund, P. J., Noone, R. M., Wilkinson, G. R., Greco, F. A. and Wolff, S. N.: Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. *Cancer Res.*, **44**: 379–382 (1984).
27) Innocenti, F., Iyer, L. and Ratain, M. J.: Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. *Drug Metab. Dispos.*, **29**: 596–600 (2001).
28) Hanioka, N., Ozawa, S., Jinno, H., Ando, M., Saito, Y. and Sawada, J.: Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. *Xenobiotica*, **31**: 687–699 (2001).
29) Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., Compton, L. D., Miller, L. L., Baker, D. S., Pesheck, C. V. and Lord, R. S. III: Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [^{14}C]CPT-11 in cancer patients. *Drug Metab. Dispos.*, **28**: 423–433 (2000).
30) Strassburg, C. P., Barut, A., Obermayer-Straub, P., Li Q, Nguyen, N., Tukey, R. H. and Manns, M. P.: Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. *J. Hepatol.*, **34**: 865–872 (2001).
31) Bernard, O. and Guillemette, C.: The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. *Drug Metab. Dispos.*, **32**: 775–758 (2004).
32) Shaw, L. M., Mick, R., Nowak, I., Korecka, M. and Brayman, K. L.: Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. *J. Clin. Pharmacol.*, **38**: 268–275 (1998).
33) Degen, P. H., Dieterle, W., Schneider, W., Theobald, W. and Sinterhauf, U.: Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. *Xenobiotica*, **18**: 1449–1455 (1988).
34) Court, M. H., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Patten, C. J., Miners, J. O. and Mackenzie, P. I.: Interindividual variability in acetaminophen glucuronidation by human liver

microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. *J. Pharmacol. Exp. Ther.*, **299**: 998–1006 (2001).
35) Ameer, B. and Greenblatt, D. J.: Acetaminophen. *Ann. Intern. Med.*, **87**: 202–209 (1977).
36) de Wildt, S. N., Kearns, G. L., Leeder, J. S. and van den Anker, J. N.: Glucuronidation in humans. Pharmacogenetic and developmental aspects. *Clin. Pharmacokinet.*, **36**: 439–452 (1999).
37) Faigle, J. W. and Feldmann, K. F.: Carbamazepine. In Woodbury, D. M. (ed.): *Antiepileptic Drugs 2nd edition*, Raven Press, New York, 1982, pp. 483–495.
38) Ethell, B. T., Anderson, G. D. and Burchell, B.: The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. *Biochem. Pharmacol.*, **65**: 1441–1449 (2003).
39) Kuhara, T., Hirokata, Y., Yamada, S. and Matsumoto, I.: Metabolism of sodium dipropylacetate in human. *Eur. J. Drug Metab. Pharmacokinet.*, **3**: 171–177 (1978).
40) Green, M. D., King, C. D. Mojarrabi, B., Mackenzie, P. I. and Tephly, T. R.: Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. *Drug Metab. Dispos.*, **26**: 507–512 (1998).
41) Luo, H., Hawes, E. M., McKay, G., Korchinski, E. D. and Midha, K. K.: N(+)-glucuronidation of aliphatic tertiary amines in human: antidepressant versus antipsychotic drugs. *Xenobiotica*, **25**: 291–301 (1995).
42) Vandel, B., Sandoz, M., Vandel, S., Allers, G. and Volmat, R.: Biotransformation of amitriptyline in depressive patients: urinary excretion of seven metabolites. *Eur. J. Clin. Pharmacol.*, **22**: 239–245 (1982).
43) Greenblatt, D. J., Schillings, R. T., Kyriakopoulos, A. A., Shader, R. I., Sisenwine, S. F., Knowles, J. A. and Ruelius, H. W.: Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral ^{14}C-lorazepam. *Clin. Pharmacol. Ther.*, **20**: 329–341 (1976).
44) Chung, J. Y., Cho, J. Y., Yu, K. S., Kim, J. R., Jung, H. R., Lim, K. S., Jang, I. J. and Shin, S. G.: Effect of the *UGT2B15* genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. *Clin. Pharmacol. Ther.*, **77**: 486–494 (2005).
45) Alvan, G., Siwers, B. and Vessman, J.: Pharmacokinetics of oxazepam in healthy volunteers. *Acta Pharmacol. Toxicol.*, **40** Suppl 1: 40–51 (1977).
46) Linnet, K.: Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. *Hum. Psychopharmacol.*, **17**: 233–238 (2002).
47) Callaghan, J. T., Bergstrom, R. F., Ptak, L. R. and Beasley, C. M.: Olanzapine. Pharmacokinetic and pharmacodynamic profile. *Clin. Pharmacokinet.*, **37**: 177–193 (1999).
48) Puozzo, C., Lens, S., Reh, C., Michaelis, K., Rosillon, D., Deroubaix, X. and Deprez, D.: Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressants. *Clin. Pharmacokinet.*, **44**: 977–988 (2005).